Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02390297 · ClinicalTrials.gov registry record
Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients
A clinical trial of HIV-1-infection and Receipt of Cal-1 Modified Hematopoietic Cellular Products, sponsored by Calimmune.
- Active
- Registry status
- 11
- Enrollment target
- 2
- Study locations
NCT02390297: Active study of HIV-1-infection and Receipt of Cal-1 Modified Hematopoietic Cellular Products, sponsored by Calimmune.
NCT02390297 is a study of HIV-1-infection and Receipt of Cal-1 Modified Hematopoietic Cellular Products that is active but no longer recruiting, run by Calimmune. The registered enrollment target is 11 participants, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02390297, a study of HIV-1-infection and Receipt of Cal-1 Modified Hematopoietic Cellular Products, is active but no longer recruiting, sponsored by Calimmune.
- ACTIVE NOT RECRUITING
- Registry status
- 11 participants
- Enrollment target
- 2
- Study locations
Study Summary
Long term safety follow-up of Cal-1 recipients
Conditions Studied
Interventions
- GENETIC Blood tests
Study Locations (2)
California
- UCLA CARE Center - Los Angeles
- Quest Clinical Research - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2015-04 |
| Est. Completion | 2031-10 |
What the registry record for NCT02390297 still lists
NCT02390297 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with HIV-1-infection appearing as the primary indexed condition, and to 1 intervention - of which Blood tests is the first listed.
NCT02390297 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02390297 about?
NCT02390297 is a clinical study titled "Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients". Long term safety follow-up of Cal-1 recipients
What is the current status of trial NCT02390297?
This trial is currently active not recruiting. The enrollment target is 11 participants. The study started on 2015-04. Estimated completion is 2031-10.
What conditions does trial NCT02390297 study?
This clinical trial studies the following conditions: HIV-1-infection, Receipt of Cal-1 Modified Hematopoietic Cellular Products.
What interventions are being tested in trial NCT02390297?
The interventions under investigation include: Blood tests (GENETIC).
Who is sponsoring clinical trial NCT02390297?
This trial is sponsored by Calimmune, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02390297 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV-1-infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02390297's enrollment target sits among peer trials
11 70th of 71 higher than 2 of 71 other HIV-1-infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV-1-infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Coronary Vascular Health in Women
RECRUITING · Phase 2
-
Study of GS-3242 in Participants With HIV-1; Substudy-05
RECRUITING · Phase 1
-
Acceptance and Commitment Therapy for HIV+ Hazardous Drinkers
RECRUITING · NA
-
Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States
RECRUITING
-
Ending the Epidemic Interventions in the Dental Setting - UH3
RECRUITING · NA
-
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia